本帖最后由 老马 于 2012-1-13 21:20 编辑 + Y+ x1 P% l! L
) q6 E5 I5 n h$ A! i
爱必妥和阿瓦斯丁的比较4 y7 f+ G8 M' U6 s, k {, Z0 F) w, x* Q
4 b" J) H9 e2 [$ c
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 I( D# e, f8 J ~. M( K0 r4 W
: A9 I* o% z! J
& W4 v$ [1 R8 J* N' hhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/6 w B5 l8 s' M, r0 j& k
==================================================
3 k+ ~/ L# c/ z' p BOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 p/ y) w- z! R' I) lPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 A* Y! V6 D2 f& D. wResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 Y( G Q6 P) q" \
|